Loading...
01/10 16:15
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call highlights strong financial performance with revenue and EPS growth, improved margins, and effective cost management. The company is actively investing in growth through product launches and strategic initiatives, including a significant share buyback plan. While there are some concerns about tariffs and Q4 EPS, the overall sentiment remains positive due to optimistic guidance and strategic investments in innovation and market expansion. The positive momentum in key business segments and capital allocation strategy supports a positive outlook for the stock price.
Revenue Revenue grew 8.5% to $5.5 billion or 3% organic. New BD organic growth was 4%. Reasons for growth include accelerated commercial initiatives, increased organic growth trajectory, and actions to optimize product supply.
Adjusted Gross Margin Adjusted gross margin was 54.8%, up 50 basis points year-over-year. This improvement was driven by BD Excellence lean operating system, manufacturing productivity, waste improvement, and network optimization.
Adjusted Operating Margin Adjusted operating margin was 25.8%, up 60 basis points year-over-year. This was supported by active management of shipping and G&A costs while investing in selling and marketing to drive growth.
Adjusted Diluted EPS Adjusted diluted EPS grew 5.1% to $3.68. This exceeded expectations due to strong execution down the P&L, including margin expansion and productivity gains.
Pharm Systems Growth Pharm Systems improved sequentially to nearly 5% growth, driven by double-digit growth in biologics and increased orders for GLP-1s. However, there was volatility in subcategories such as generic anticoagulants and vaccines.
APM Growth APM delivered 13% pro forma growth in the quarter. This was driven by strong commercial execution, incremental selling investment, and new product innovation, including the HemoSphere Alta Monitor.
Interventional Segment Growth The Interventional segment delivered nearly 7% growth, with 12% growth in UCC supported by new product launches like PureWick Flex at Home and PureWick Male.
Life Sciences Segment Biosciences and Diagnostic Solutions decreased low single digits year-over-year but showed sequential positive momentum of approximately 250 basis points. Growth was driven by reagents and service, offset by a decrease in instrument sales due to market dynamics in China and Europe.
Free Cash Flow Year-to-date free cash flows were approximately $1.7 billion, increasing sequentially by $1 billion. This was driven by productivity gains, improved collections, and timing of payables, partially offset by increased inventory levels and cash payments related to tariffs.
FACSDiscover A8: Launched with breakthrough spectral and real-time cell imaging technologies, exceeding sales targets.
BD Libertas Wearable Injector: Entered first pharma-sponsored clinical trial for self-injection of complex biologic drugs.
CentroVena One: Received FDA clearance for rapid insertion central catheter, targeting $500 million central line market.
Phasix: Expanded indications with EU launch of world's first resorbable scaffold for hernia prevention.
BD Pyxis Pro: Limited commercial release with AI features to improve nurse workflow and productivity.
China market dynamics: Continued market headwinds in China, particularly in life sciences and Pharm Systems subcategories.
HPV testing market: BD COR platform addressing $1 billion market for HPV testing with FDA submission for at-home self-collection kit.
GLP-1 biosimilars: Expanded agreements to over 70, with biologics now representing 50% of Pharm System sales.
BD Excellence operating system: Improved manufacturing productivity, reduced waste by over 35%, and increased equipment efficiency, creating capacity for 2.5 billion additional units.
Customer service levels: Achieved highest on-time in full deliveries in over 5 years.
Biosciences and Diagnostics business separation: Announced agreement to combine with Waters through a tax-efficient Reverse Morris Trust, expected to close by Q1 2026.
Capital allocation strategy: Plan to use $4 billion cash distribution from Waters for share buybacks and debt repayment.
Market Headwinds in China: Continued market headwinds in China, particularly in certain subsegments of Pharm Systems such as vaccines and the life science research market, are impacting growth.
Regulatory and Tariff Impacts: The company faces a significant tariff impact of about $90 million for the full year 2025, predominantly weighted to Q4, and an anticipated $275 million impact in fiscal 2026. This creates financial pressure and necessitates mitigation efforts.
Supply Chain and Manufacturing Challenges: While BD Excellence has improved manufacturing productivity and waste reduction, the company still faces challenges related to inventory levels and cash payments tied to tariffs.
Economic Volatility in Subcategories: Volatility in subcategories such as generic anticoagulants and vaccines remains a concern, impacting Pharm Systems' performance.
Research Funding Constraints: Research funding constraints in Europe and market dynamics in China are affecting the Biosciences segment, particularly in instrument sales.
Volume-Based Procurement Pressure in China: The Medical Delivery Solutions (MDS) segment is experiencing pressure from volume-based procurement policies in China, impacting growth.
Integration and Separation Risks: The planned separation of the Biosciences and Diagnostics business and its integration with Waters involves execution risks, including potential disruptions and challenges in achieving anticipated synergies.
Competitive Pressures: The company faces competitive pressures in securing wins in the infusion and dispensing markets, as well as in the adoption of new products like Pyxis Pro and Alaris.
Economic Uncertainty in Key Markets: Economic uncertainty in key markets, including the U.S. and Europe, poses risks to growth and stability.
Revenue Guidance: Reaffirmed currency-neutral revenue guidance, including total revenue growth of 7.8% to 8.3% and organic revenue growth of 3% to 3.5% for fiscal 2025. Year-over-year organic growth is expected to improve sequentially in Q4.
Earnings Guidance: Raised adjusted EPS guidance by $0.18 at the midpoint to a range of $14.30 to $14.45, reflecting growth of about 9.4% at the midpoint. This includes an estimated tariff impact of about $90 million or 2% to EPS growth for the full year.
Tariff Impact: For fiscal 2026, the full year tariff impact is anticipated to be around $275 million, reflecting ongoing mitigation efforts and moderated tariff rates.
Innovation Pipeline: Several product launches and milestones are expected in fiscal 2026, including the next-generation BACTEC launch, new assays for BD MAX, and the first-ever at-home self-collection kit for HPV screening, with FDA approval expected in mid-FY '26.
Connected Care Solutions: Limited commercial release of BD Pyxis Pro has begun, with further developments in connected care solutions expected over the next few years, including integration of Alaris infusion system and HemoSphere Alta Monitor.
Biosciences and Diagnostics Business: The separation of the Biosciences and Diagnostics business through a Reverse Morris Trust with Waters is progressing towards an expected closing around the end of Q1 2026.
Capital Allocation: Plans to use at least half of the approximately $4 billion cash distribution from Waters for share buybacks, with the balance for debt repayment, aiming for a 2.5x long-term net leverage target.
Dividend Payments: The company continues to pay competitive dividends as part of its capital allocation strategy.
Share Buybacks: The company emphasized share buybacks as a key component of its capital allocation strategy. At least half of the approximately $4 billion cash distribution from Waters will be used to buy back shares, with the balance allocated for debt repayment. Additionally, the company expects to complete its $1 billion buyback by the end of September, ahead of the original commitment.
The earnings call summary and Q&A reflect a positive sentiment. The company reported strong financial performance, including high single-digit growth in key areas and margin expansion. The guidance was conservative yet confident, with raised EPS expectations and strategic share buybacks. Despite some uncertainties, the overall outlook is optimistic, with a focus on innovation and commercial excellence. The market strategy and shareholder return plans are likely to be well-received, leading to a positive stock price movement.
The earnings call highlights strong financial performance with revenue and EPS growth, improved margins, and effective cost management. The company is actively investing in growth through product launches and strategic initiatives, including a significant share buyback plan. While there are some concerns about tariffs and Q4 EPS, the overall sentiment remains positive due to optimistic guidance and strategic investments in innovation and market expansion. The positive momentum in key business segments and capital allocation strategy supports a positive outlook for the stock price.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
